MEDIPOST Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 04:51 am EDT
Share
MEDIPOST Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 16,651.9 million compared to KRW 15,950.54 million a year ago. Net income was KRW 3,527.76 million compared to net loss of KRW 11,388.35 million a year ago. Basic earnings per share from continuing operations was KRW 219 compared to basic loss per share from continuing operations of KRW 705 a year ago. Diluted earnings per share from continuing operations was KRW 219 compared to diluted loss per share from continuing operations of KRW 705 a year ago. Basic earnings per share was KRW 219 compared to basic loss per share of KRW 705 a year ago.
For the six months, sales was KRW 2,579.17 million compared to KRW 2,517.53 million a year ago. Net loss was KRW 2,737.87 million compared to KRW 17,885.21 million a year ago. Basic loss per share from continuing operations was KRW 170 compared to KRW 1,108 a year ago. Diluted loss per share from continuing operations was KRW 170 compared to KRW 1,108 a year ago. Basic loss per share was KRW 170 compared to KRW 1,108 a year ago.
MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
MEDIPOST CO., LTD. 
